ADA: Lilly, Boehringer's DPP-4 drug Tradjenta ties generic rival in heart safety study

Boehringer Ingelheim and Eli Lilly have already shown that Tradjenta doesn’t hurt patients’ hearts. But the pair is back with even more supporting evidence that they hope will bolster the drug's profile in a competitive field.

Monday at the American Diabetes Association annual meeting, the companies rolled out results showing Tradjenta didn’t increase cardiovascular risks for Type 2 diabetes patients when pitted against generically available glimepiride.